A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Bryce, Alan Haruo
Karp, Daniel D.
Tagawa, Scott T.
Nordquist, Luke T.
Rathkopf, Dana E.
Adra, Nabil
Dorff, Tanya B.
Baeck, Johan
O'Donnell, Joseph Francis
Ames, Tyler David
Yim, Christina Y.
Price, Matthew
Scher, Howard I.
机构：
[1] Mayo Clin, Phoenix, AZ USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Cornell Univ, Weill Cornell Med Coll, New York, NY USA
[4] Urol Canc Ctr PC, Omaha, NE USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Weill Cornell Med, New York, NY USA
[7] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
[8] City Hope Natl Med Ctr, Duarte, CA USA
[9] Promontory Therapeut Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS292
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08) : e2428444
  • [32] Heterogeneity of canonical prostate cancer markers across lesions in metastatic castration-resistant prostate cancer.
    Trigos, Anna S.
    Pasam, Anupama
    Inderjeeth, Andrisha-Jade
    Cain, Lachlan D.
    Weng, Sirui
    Gupta, Vinita
    Sable, Beate
    Paweletz, Katherine L.
    Bailis, Julie M.
    Zhang, Yangyi
    Feng, Yuzhou
    Anton, Angelyn
    Tran, Ben
    Mitchell, Catherine
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [33] A phase II study of onvansertib (PCM-075) in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer.
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] Evolocumab in Metastatic Castration-Resistant Prostate Cancer - study schema
    Mellor, Rhiannon
    Ardolino, Luke
    Scheinberg, Tahlia
    Sullivan, David
    Lin Hui-Ming
    Meikle, Peter
    Stockler, Martin
    Joshua, Anthony
    Horvath, Lisa
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 68 - 68
  • [35] Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    Dahut, William L.
    Madan, Ravi A.
    Karakunnel, Joyson J.
    Adelberg, David
    Gulley, James L.
    Turkbey, Ismail B.
    Chau, Cindy H.
    Spencer, Shawn D.
    Mulquin, Marcia
    Wright, John
    Parnes, Howard L.
    Steinberg, Seth M.
    Choyke, Peter L.
    Figg, William D.
    BJU INTERNATIONAL, 2013, 111 (08) : 1269 - 1280
  • [36] Targeting mitochondria and programmed cell death as potential interventions for metastatic castration-resistant prostate cancer
    Amantakul, Amonlaya
    Amantakul, Akara
    Pojchamarnwiputh, Suwalee
    Chattipakorn, Nipon
    Chattipakorn, Siriporn Chaisin
    Sripetchwandee, Jirapas
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [37] Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
    Winquist, Eric
    Hotte, Sebastien J.
    Chi, Kim
    Sridhar, Srikala
    Ellard, Susan
    Ong, Michael
    Iqbal, Nayyer
    Salim, Muhammad
    Emmenegger, Urban
    Gingerich, Joel R.
    Lalani, Aly-Khan
    Major, Pierre
    Kollmannsberger, Christian
    Yip, Steven
    Hansen, Aaron
    Finch, Daygen
    Canil, Christina
    Hutchenreuther, James
    Vera-Badillo, Francisco
    Smoragiewicz, Martin
    Cabanero, Michael
    Tsao, Ming-Sound
    Ritch, Elie
    Wyatt, Alexander W.
    Seymour, Lesley
    CLINICAL CANCER RESEARCH, 2025, 31 (01) : 45 - 55
  • [38] A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Danila, Daniel Costin
    Waterhouse, David Michael
    Appleman, Leonard Joseph
    Pook, David William
    Matsubara, Nobuaki
    Dorff, Tanya B.
    Lee, Jae-Lyun
    Armstrong, Andrew J.
    Kim, Miso
    Horvath, Lisa
    Sumey, Christopher Joseph
    Cooner, Freda
    Salvati, Mark
    Stieglmaier, Julia
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] A drug-drug interaction study on the combination of cabazitaxel with enzalutamide in patients with metastatic castration-resistant prostate cancer.
    Belderbos, Bodine P. S.
    Bins, Sander
    van Leeuwen, Roelof W. F.
    De Hoop, Esther Omen
    van der Meer, Nelly
    de Bruijn, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [40] Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
    Kongsted, Per
    Borch, Troels Holz
    Ellebaek, Eva
    Iversen, Trine Zeeberg
    Andersen, Rikke
    Met, Ozcan
    Hansen, Morten
    Lindberg, Henriette
    Sengelov, Lisa
    Svane, Inge Marie
    CYTOTHERAPY, 2017, 19 (04) : 500 - 513
12345